New Research on Anatabine's Beneficial Effect on Alzheimer's Disease Presented at Neuroscience 2012

New Research on Anatabine's Beneficial Effect on Alzheimer's Disease Presented
                             at Neuroscience 2012

PR Newswire

GLEN ALLEN, Va., Oct. 17, 2012

GLEN ALLEN, Va., Oct. 17, 2012 /PRNewswire/ --Star Scientific, Inc. (NASDAQ:
STSI) through its wholly owned subsidiary, Rock Creek Pharmaceuticals Inc.,
reports that scientists from its research partner, the Roskamp Institute,
presented research this week showing that anatabine supplementationreduces
the pathology and signsin an animal model ofAlzheimer's disease. The
findings were presented in New Orleans, Louisiana,at Neuroscience 2012, the
42nd annual meeting of the Society for Neuroscience,as part of a series of
presentations by researchers from the Roskamp Institute on supplementation
with anatabine, the active ingredient in the Company's Anatabloc® dietary
supplement. Neuroscience2012isthe world's largest and most prestigious
scientific meeting dedicated to brain and neurological science,with more than
32,000 neuroscientistsfrom around the world gathering to observe and
participate in presentations relating to more than 16,000 new discoveries in
science and health.

(Logo: )

Megha Vermaof the Roskamp Institutedeliveredtheposter presentation
titled,"Anti-Inflammatory and Amyloid Beta Lowering Properties of Anatabine
in a Transgenic Mouse Model of Alzheimer's Disease",in which
scientistsreported that anatabine treated Alzheimer's mice retained their
memory and learning compared to the untreated Alzheimer's mice. Dr. Michael
Mullan, President and CEO of the Roskamp Institute, stated, "In examining how
anatabine works, the researchers show that key molecules which govern
inflammation were deactivated, and this is important because we know that
inflammation both promotes and maintains the deterioration of the brain in
Alzheimer's disease." 

Last year, the Company reported the publication of the first peer-reviewed
article on the in-vitro and in-vivo activity of anatabine in Alzheimer's
Disease in the European Journal of Pharmacology (Paris et al. 2011 Sept 19).
This week's presentation in New Orleans expands upon that published work and
marks the first time the data have been presented at an international
scientific convention.

In addition to the research on Alzheimer's disease, earlier in the conference,
the Roskamp Institute presented results of research examining the potential
benefit of anatabine for alleviating symptoms associated with multiple
sclerosis and in helping with recovery from traumatic brain injury. (To view
the Company's press releases on these presentations, click here:

Certain statements contained in this release constitute forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. Such statements include, but are not limited to statements identified
by words such as "believes," "expects," "anticipates," "estimates," "intends,"
"plans," "targets," "projects" and similar expressions. The statements in this
release are based upon the current beliefs and expectations of our company's
management and are subject to significant risks and uncertainties. Actual
results may differ from those set forth in the forward-looking statements.
Numerous factors could cause or contribute to such differences, including, but
not limited to, results of clinical trials, the challenges inherent in new
product development initiatives, including the continued development and
market acceptance of our nutraceutical and low-TSNA tobacco products, our
ability to license and protect our intellectual property, our ability to raise
additional capital in the future that is necessary to maintain our business,
changes in government policy and/or regulation, including with respect to our
nutraceutical and low-TSNA tobacco products, as well as other risks discussed
from time to time in our filings with the Securities and Exchange Commission,
including, without limitation, our annual report on Form 10-K for the fiscal
year ended December 31, 2011. We undertake no duty to update any
forward-looking statement or any information contained in this press release
or in other public disclosures at any time.

About Star Scientific
Star Scientific, Inc. is a technology-oriented company with a mission to
promote maintenance of a healthy metabolism, as well as to reduce the harm
associated with the use of tobacco at every level. Over the last several
years, through its wholly owned subsidiary, Rock Creek Pharmaceuticals, Star
Scientific has been engaged in the manufacturing, sale, and marketing of two
nutraceutical dietary supplements, and the development of other nutraceuticals
and pharmaceuticals. The company also has continued to pursue the development,
implementation, and licensing of the technology behind its proprietary
StarCured® tobacco curing process, which substantially prevents the formation
of carcinogenic toxins present in tobacco and tobacco smoke, primarily the
tobacco-specific nitrosamines, or TSNAs and related low-TSNA dissolvable
tobacco products. Rock Creek Pharmaceuticals has scientific and research
offices in Gloucester, MA, and a regulatory office in Washington, DC. Star
Scientific has a Corporate and Sales Office in Glen Allen, VA; Executive,
Scientific & Regulatory Affairs offices in Bethesda, MD, and Washington, DC;
and a manufacturing facility in Chase City, VA.


Talhia T. Tuck 

Vice President, Communications and Investor Relations 

Star Scientific, Inc. 


SOURCE Star Scientific, Inc.

Press spacebar to pause and continue. Press esc to stop.